{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Ianza A"],"pubmed_abstract":["Over the last two decades, many studies have demonstrated that the insulin-like growth factor-1 (IGF-1) is involved in a number of patho-physiological processes, as well as in the development of different types of solid tumors, including breast cancer (BC). Preclinical and clinical data showed that IGF-1 receptor (R) is overexpressed and hyper-phosphorylated in several subtypes of BCs. The central implications of this pathway in tumor cell proliferation and metastasis make it an important therapeutic target. Moreover, the IGF-1 axis has shown strong interconnection with estrogen regulation and endocrine therapy, suggesting a possible solution to anti-estrogen resistance. IGF-1R might also interfere with other pivotal therapeutic strategies, such as anti HER2 treatments and mTOR inhibitors; several clinical trials are ongoing evaluating the role of IGF-1R inhibition in modulating resistance mechanisms to target therapies. Our aim is to offer an overview of the most recent and significant field of application of IGF-1 inhibitors and relevant therapeutic strategies, weighing their possible future impact on clinical practice."],"journal":["Frontiers in cell and developmental biology"],"pagination":["641449"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8019779"],"repository":["biostudies-literature"],"pubmed_title":["Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer."],"pmcid":["PMC8019779"],"pubmed_authors":["Bernocchi O","Generali D","Sirico M","Ianza A"],"additional_accession":[]},"is_claimable":false,"name":"Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer.","description":"Over the last two decades, many studies have demonstrated that the insulin-like growth factor-1 (IGF-1) is involved in a number of patho-physiological processes, as well as in the development of different types of solid tumors, including breast cancer (BC). Preclinical and clinical data showed that IGF-1 receptor (R) is overexpressed and hyper-phosphorylated in several subtypes of BCs. The central implications of this pathway in tumor cell proliferation and metastasis make it an important therapeutic target. Moreover, the IGF-1 axis has shown strong interconnection with estrogen regulation and endocrine therapy, suggesting a possible solution to anti-estrogen resistance. IGF-1R might also interfere with other pivotal therapeutic strategies, such as anti HER2 treatments and mTOR inhibitors; several clinical trials are ongoing evaluating the role of IGF-1R inhibition in modulating resistance mechanisms to target therapies. Our aim is to offer an overview of the most recent and significant field of application of IGF-1 inhibitors and relevant therapeutic strategies, weighing their possible future impact on clinical practice.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-04T07:38:27.82Z","creation":"2022-02-09T14:25:23.918Z"},"accession":"S-EPMC8019779","cross_references":{"pubmed":["33829018"],"doi":["10.3389/fcell.2021.641449"]}}